Fiche centre
Hospital Clinico Universitario de Valladolid
Valladolid — Spain
Essais liés17clinical trials
VilleValladolidlocalisation
PaysSpainlocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04396574
Essais cliniques associés
17| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Sotorasib | Cancer | Phase 3 | NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396236 | PIONEER-PEDS1 — A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| AMG334 | Migraine | Phase 4 | NCT03927144 | Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients | COMPLETED |
| Galcanezumab | Migraine | Phase 3 | NCT04616326 | REBUILD-2 — A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine | ACTIVE_NOT_RECRUITING |
| Lasmiditan | Migraine | Phase 3 | NCT04396574 | PIONEER-PEDS2 — A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine | TERMINATED |
| Fremanezumab Prefilled Syringe | Migraine | Phase 4 | NCT06244823 | The FreMRI Study: Advanced MRI on Migraine Patients Treated With Fremanezumab | UNKNOWN |
| Patients with migraine treated with triptans, Lasmiditan or Gepants | Migraine | À vérifier | NCT06267664 | Real-world Effectiveness and Tolerability of Triptans-Ditans-Gepants (TRIDIGEP) | UNKNOWN |
| Monoclonal antibody anti-CGRP | Migraine | À vérifier | NCT06459648 | PREDI-CGRP — Study for Prevent Chronification Migraine Through Prediction of Response to Treatment With Anti-CGRP Antibodies | RECRUITING |
| Rimegepant | Migraine | Phase 3 | NCT06641466 | A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine | RECRUITING |
| Galcanezumab | Migraine | Phase 3 | NCT03432286 | REBUILD-1 — A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine | ACTIVE_NOT_RECRUITING |
| Erenumab | Migraine | Phase 4 | NCT04252742 | EMBRACE — Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine | COMPLETED |
| Rimegepant | Migraine | Phase 3 | NCT06616194 | A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine | ACTIVE_NOT_RECRUITING |
| Rimegepant (PF-07899801) | Migraine | Phase 3 | NCT04743141 | Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05667142 | X-ACKT — A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures | RECRUITING |
| XEN1101 | Épilepsie | Phase 3 | NCT05718817 | X-TOLE4 — An Open-label Study of XEN1101 in Epilepsy | ENROLLING_BY_INVITATION |
| BHV-7000 | Épilepsie | Phase 2/3 | NCT06309966 | RISE 3 — Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | ACTIVE_NOT_RECRUITING |
| Rimegepant/BHV3000 | Migraine | Phase 3 | NCT04649242 | Randomized Study in Children and Adolescents With Migraine: Acute Treatment | RECRUITING |